scholarly journals NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022

2021 ◽  
Vol 19 (12) ◽  
pp. 1382-1394
Author(s):  
Chrysalyne D. Schmults ◽  
Rachel Blitzblau ◽  
Sumaira Z. Aasi ◽  
Murad Alam ◽  
James S. Andersen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Skin Cancer ◽  
Squamous Cell ◽  
Clinical Stage ◽  
Treatment Options ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Margin Assessment ◽  
Nccn Guidelines ◽  
Institutional Review ◽  
En Face

The NCCN Guidelines for Squamous Cell Skin Cancer provide recommendations for diagnostic workup, clinical stage, and treatment options for patients with cutaneous squamous cell carcinoma. The NCCN panel meets annually to discuss updates to the guidelines based on comments from panel members and the Institutional Review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new surgical recommendation terminology (peripheral and deep en face margin assessment), as well as recent updates on topical prophylaxis, immunotherapy for regional and metastatic disease, and radiation therapy.

scholarly journals Molecular Approach to Cutaneous Squamous Cell Carcinoma: From Pathways to Therapy

2020 ◽  
Vol 21 (4) ◽  
pp. 1211
Author(s):  
Elisabetta Palazzo ◽  
Maria I. Morasso ◽  
Carlo Pincelli
Keyword(s):  
United States ◽  
Squamous Cell Carcinoma ◽  
Skin Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
The United States ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Molecular Approach

Cutaneous squamous cell carcinoma (cSCC) represents the second most frequent skin cancer, recently showing a rapid increase in incidence worldwide, with around >1 million cases/year in the United States and 2500 deaths [...]

Invasive Cutaneous Squamous Cell Carcinoma Presenting as a Nonhealing Radiation Wound

2011 ◽  
Vol 101 (4) ◽  
pp. 360-362
Author(s):  
Stephen J. Longobardi ◽  
Brian Sullivan ◽  
E. Hani Mansour
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
Skin Cancer ◽  
Cell Carcinoma ◽  
Malignant Transformation ◽  
Squamous Cell ◽  
Lower Extremities ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Invasive Squamous Cell Carcinoma ◽  
Negative Biopsy

Cutaneous squamous cell carcinoma is the second most common form of skin cancer and accounts for 20% of cutaneous malignancies. We report the case of a patient who presented with a complaint of nonhealing wounds following radiation therapy for the treatment of noninvasive squamous cell carcinoma of both lower extremities. Initial biopsies of the wounds were benign. However, a second biopsy performed approximately 2 months later was found to be positive for invasive squamous cell carcinoma. This case uniquely exemplifies that all nonhealing wounds should be viewed with a critical eye for possible malignancy even in the presence of previous negative biopsy. This is especially true for radiation wounds that may be prone to malignant transformation or recurrence. (J Am Podiatr Med Assoc 101(4): 360–362, 2011)

Skin Cancer Knowledge and Preventive Behaviors among Patients with a Recent History of Cutaneous Squamous Cell Carcinoma

Dermatology ◽  
2008 ◽  
Vol 217 (1) ◽  
pp. 74-80 ◽  
Author(s):  
Cristina Renzi ◽  
Simona Mastroeni ◽  
Thomas J. Mannooranparampil ◽  
Francesca Passarelli ◽  
Alessio Caggiati ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Skin Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Recent History ◽  
Cancer Knowledge ◽  
Preventive Behaviors ◽  
History Of

Squamous Cell Carcinoma: Epidemiology, Risk Factors, and Treatment Options

2017 ◽  
Author(s):  
Jeffrey M Farma ◽  
Elena P Lamb
Keyword(s):  
Risk Factors ◽  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
High Risk ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Options ◽  
Primary Treatment ◽  
Surgical Margins ◽  
Margin Assessment

Ultraviolent (UV) solar radiation is considered to be the dominant risk factor for development of squamous cell carcinoma (SCC). The development of SCC appears to be linked to the cumulative dose of UV radiation over time. Identifying patients with high-risk factors for developing SCC includes chronic immunosuppression, exposure to ionizing radiation, and certain genetic syndromes. Primary treatment goals of cutaneous SCC include cure of tumor with maximal preservation of function. Treatment options should be stratified for low- and high-risk SCC. Primary treatment options for low-risk SCC include (1) curettage and electrodesiccation, (2) excision with postoperative margin assessment (POMA) with 4 to 6 mm margins, and (3) radiation therapy (RT) for nonsurgical candidates. Options for high-risk SCC lesions include (1) Mohs surgery or resection with complete circumferential peripheral and deep margin assessment, (2) excision with POMA with wider surgical margins and primary or delayed repair, and (3) RT for nonsurgical candidates.     This review contains 4 figures, 5 tables, and 32 references. Key words: cutaneous squamous cell carcinoma, Mohs micrographic surgery, pathologic risk factors, radiation therapy, surgical margins 

Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma

2019 ◽  
Vol 15 (27) ◽  
pp. 3171-3184 ◽  
Author(s):  
Erik T Petersen ◽  
Saqib R Ahmed ◽  
Leon Chen ◽  
Sirunya Silapunt ◽  
Michael R Migden
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Options ◽  
Poor Response ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Significant Treatment ◽  
Fda Approval ◽  
Us Fda ◽  
First Time

Advanced cutaneous squamous cell carcinoma (cSCC) accounts for only 5% of all cases of cSCC but up to 60% of disease related deaths. Historically, this disease has lacked effective treatment options due to a combination of poor response rate, poor response durability and significant treatment-associated morbidity. Autumn of 2018 marked the first time ever that an agent received US FDA approval for advanced cSCC and the future is looking much brighter for this previously neglected patient population. The purpose of this article is to review the various systemic treatment options for advanced cSCC moving from the past to the present, highlighting their relative merits and shortcomings, and to briefly speculate on future developments in the field of advanced cSCC.

scholarly journals An online review of informational sources for advanced or high-risk cutaneous squamous cell carcinoma

2021 ◽  
Author(s):  
Rachel Starkings ◽  
Valerie Shilling ◽  
Lesley Fallowfield
Keyword(s):  
Squamous Cell Carcinoma ◽  
High Risk ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Advanced Disease ◽  
Treatment Options ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Online Information ◽  
Eligibility Criteria ◽  
Treatment Pathways

Abstract Objective Cutaneous squamous cell carcinoma (cSCC) is one of the most prevalent non-melanoma skin cancers worldwide. While usually treatable, patients with high-risk or advanced disease have few treatment options and limited resources available. This review assesses what online information resources are available to patients and their families about either high-risk or advanced cSCC. Methods Searches were run, via Google, using 8 terms such as ‘advanced cutaneous squamous cell carcinoma patient information’. Advertisements were removed and the first 3 pages/30 results from each search were screened for duplicates and then against eligibility criteria. Websites needed to have been updated within the past 5 years, be freely accessible, designed specifically for patients and refer to the advanced disease or high-risk setting. Remaining results were assessed using the DISCERN tool. Results Of the final 240 results, 121 were duplicates and 104 were ineligible. The remaining 15 sources were predominantly aimed at American audiences, used variable terminology and revealed differing treatment pathways. Only 3 sites were deemed as ‘high’-quality information sources. Conclusion There is a lack of accessible online information on high-risk or advanced cSCC for patients. What is available is often too scientific or clinical and lacks clarity about the disease and treatment options. Practice Implications Further work is needed to improve the integrity and accessibility of online sources and to signpost patients to the most reliable information. This should include elements of patient led research, clinical education and information development.

scholarly journals High-risk Cutaneous Squamous Cell Carcinoma

2017 ◽  
Vol 8 (2) ◽  
pp. 37-44
Author(s):  
C Fitzgerald ◽  
James Paul O'Neill
Keyword(s):  
Squamous Cell Carcinoma ◽  
High Risk ◽  
Skin Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Patient Characteristics ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Pathological Features ◽  
Current Guidelines ◽  
Head Neck

ABSTRACT Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer worldwide. Cutaneous squamous cell carcinoma can potentially be treated fully with minimal morbidity when detected early; however, certain subtypes of cSCC have been shown to confer a poorer prognosis for patients. In these high-risk tumors, increased incidence of recurrence, as well as metastasis to local lymph nodes and distant sites, is seen as a result of certain patient characteristics and pathological features. While guidelines regarding the management of high-risk cSCC have been produced, no clear consensus management or prognostic algorithms exist. In this review, we discuss current definitions of high-risk cSCC, recommendations regarding the management of cSCC, and current guidelines. How to cite this article Fitzgerald C, O'Neill JP. High-risk Cutaneous Squamous Cell Carcinoma. Int J Head Neck Surg 2017;8(2):37-44.

Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective

2021 ◽  
Author(s):  
Kelly M Wilmas ◽  
Quoc-Bao Nguyen ◽  
Jigar Patel ◽  
Sirunya Silapunt ◽  
Michael R Migden
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
Antitumor Activity ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Options ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Durable Response ◽  
Alternative Approach

Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The introduction of immunotherapy with anti-PD-1 antibodies resulted in alternative treatment options for advanced cutaneous squamous cell carcinoma with substantial antitumor activity, durable response and acceptable safety profile. The field of immunotherapeutics continues to expand with adjuvant, neoadjuvant and intralesional studies currently in progress. Herein, the authors discuss their approach for the treatment of advanced cutaneous squamous cell carcinoma from the perspective of a Mohs surgeon and a dermatologic oncologist.

Sign in / Sign up

Export Citation Format

Share Document